Weiss Ratings Reaffirms "Hold (C)" Rating for Semler Scientific (NASDAQ:SMLR)

Key Points

• Weiss Ratings has reaffirmed a "Hold (C)" rating for Semler Scientific (NASDAQ:SMLR) in their latest research report.
• Several analysts have adjusted their price targets for Semler, with Maxim Group lowering it from $95.00 to $80.00 while maintaining a "buy" rating.
• Semler Scientific reported earnings of $5.04 per share for the latest quarter, significantly surpassing the consensus estimate of (0.27) by $5.31.

Semler Scientific (NASDAQ:SMLR - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

SMLR has been the topic of several other reports. Maxim Group dropped their price target on Semler Scientific from $95.00 to $80.00 and set a "buy" rating on the stock in a research report on Friday, September 19th. Benchmark dropped their price target on Semler Scientific from $101.00 to $86.00 and set a "buy" rating on the stock in a research report on Tuesday, September 23rd. Finally, Cantor Fitzgerald dropped their price target on Semler Scientific from $61.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $74.25.

Semler Scientific Stock Performance

Shares of SMLR opened at $28.20 on Wednesday. The business's 50 day moving average is $31.18 and its two-hundred day moving average is $34.97. Semler Scientific has a 52-week low of $25.10 and a 52-week high of $81.56. The firm has a market cap of $426.95 million, a price-to-earnings ratio of 11.60 and a beta of 1.41. The company has a quick ratio of 0.58, a current ratio of 0.60 and a debt-to-equity ratio of 0.25.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $5.31. The business had revenue of $8.22 million for the quarter, compared to analyst estimates of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SMLR. Summit Securities Group LLC bought a new position in Semler Scientific during the 1st quarter worth $32,000. SBI Securities Co. Ltd. grew its stake in shares of Semler Scientific by 161.3% in the first quarter. SBI Securities Co. Ltd. now owns 959 shares of the company's stock worth $35,000 after purchasing an additional 592 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Semler Scientific by 75.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 1,674 shares of the company's stock worth $65,000 after purchasing an additional 720 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Semler Scientific by 354.8% in the second quarter. Tower Research Capital LLC TRC now owns 1,819 shares of the company's stock worth $70,000 after purchasing an additional 1,419 shares in the last quarter. Finally, Corebridge Financial Inc. grew its stake in shares of Semler Scientific by 39.7% in the first quarter. Corebridge Financial Inc. now owns 3,298 shares of the company's stock worth $119,000 after purchasing an additional 938 shares in the last quarter. 49.37% of the stock is currently owned by institutional investors.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.